NASDAQ
30.94USD
+0.63 (+2.09%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.9B
P/E
—
EPS
—
Beta
1.48
52W range
2.45-38.325
Day range
30.55–31.64
Open
30.55
Prev close
30.31
Volume
68K
Avg volume
498.6K
Dividend
0.00
IPO
2020-10-29
https://www.defenseworld.net/2026/03/29/fb-bancorp-inc-nasdaqfbla-short-interest-update.html · 3/29/2026+0.40
https://www.defenseworld.net/2026/03/29/damora-therapeutics-inc-common-stock-nasdaqdmra-given-average-rating-of-moderate-buy-by-analysts.html · 3/29/2026+0.60
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
